Virpax Pharmaceuticals, Inc. - VRPX STOCK NEWS

Virpax Pharmaceuticals (NASDAQ:VRPX) reported its financial results for Q2 2021, revealing a significant operating loss of approximately $2.3 million, up from $1.2 million in Q2 2020. General and administrative expenses rose to $2 million, driven by legal fees. Research and development expenses increased to $0.3 million, influenced by activities related to product candidates Epoladerm and Probudur. The company is advancing its product pipeline, including Epoladerm and Probudur, and engaged Syneos Health to develop regulatory pathways for its anti-viral candidate MMS019.

Virpax Pharmaceuticals (NASDAQ: VRPX) has appointed Gerald W. Bruce and Michael F. Dubin, CPA, to its Board of Directors. Bruce, with over 30 years in the pharmaceutical industry, has held significant roles at NitroMed and Bristol-Myers Squibb. Dubin brings 40 years of experience in various sectors, including pharma and financial services, and was previously Managing Partner at RSMUS LLP. Chairman and CEO Anthony P. Mack expressed optimism about the new members' contributions to the company’s strategic direction in pain management products.

Virpax Pharmaceuticals Inc. (NASDAQ:VRPX) provided an update on its product pipeline post-IPO. CEO Anthony Mack highlighted progress towards becoming a clinical stage company while focusing on cost preservation. Key developments include refinements to formulations, with plans to initiate Investigational New Drug (IND) studies on multiple programs. Epoladerm, Probudur, Envelta, and MMS019 are highlighted candidates. MMS019 showed promising results in animal studies, showing inhibited viral replication. The company is enthusiastic about future opportunities and will share further updates through regulatory filings.

Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) has announced that its IND application for Envelta™, an investigational intranasal formulation for chronic pain, will also serve as a basis for additional INDs targeting cancer pain and PTSD. Under a CRADA with NCATS, IND enabling studies have begun, paving the way for FDA submission. Envelta™ aims to enhance enkephalin delivery to the brain, showing analgesic potential without the adverse effects typical of opioids. Virpax is also developing other products, including Epoladerm™ and Probudur™, to address pain management.

Virpax Pharmaceuticals (NASDAQ:VRPX) announced its virtual presentation at the LD Micro Invitational XI on June 9, 2021, at 4:30 PM ET. Anthony Mack, Chairman and CEO, will present the company's non-addictive pain management products, including Epoladerm™, Probudur™, and Envelta™. The event runs from June 8-10, featuring about 180 companies. Virpax focuses on innovative, proprietary drug delivery technologies aimed at FDA approval for its offerings, targeting conditions like pain management and PTSD.

Virpax Pharmaceuticals (NASDAQ:VRPX) announced its Q1 2021 financial results, highlighting a successful IPO of 1.8 million shares at $10 each, raising $18 million. The company has initiated IND enabling studies for its product candidates Epoladerm and Envelta, with promising preclinical results for Probudur and MMS019 showing no nerve damage and inhibition of viral replication, respectively. Operating loss increased to $2.3 million, with cash used in operations rising to $3.08 million. As of March 31, 2021, cash and equivalents stood at approximately $12.3 million.

Virpax Pharmaceuticals (NASDAQ:VRPX) has engaged Torreya Capital, LLC as its exclusive financial advisor for global licensing and partnership efforts. Torreya has a strong track record in the life sciences sector, facilitating over $100 billion in transactions since 2007. CEO Anthony Mack emphasized the rising demand for non-opioid pain relief, citing their product candidates: Epoladerm™, Probudur™, and Envelta™. Torreya aims to locate strong regional partners to enhance Virpax's innovative pipeline focused on non-addictive pain management solutions.

Virpax Pharmaceuticals (NASDAQ:VRPX) announced promising results from an animal study on MMS019, its anti-viral candidate for respiratory viruses. Led by Professor Krzysztof Pyrc, the study showed that MMS019 inhibited viral replication in the nasal passages of treated mice. Additionally, reduced virus levels were noted in brain tissue, which may have implications for neurological impacts of severe COVID-19. The Company is collaborating with Syneos Health to navigate regulatory pathways for an NDA submission to the FDA.

Virpax Pharmaceuticals (NASDAQ:VRPX) announced positive results from a preclinical study on its liposomal bupivacaine product, Probudur™. The study assessed neurotoxicity in rabbits, revealing no motor or sensory nerve damage at doses 10 times higher than free bupivacaine. While free bupivacaine showed mild neurotoxicity, Probudur™ demonstrated a favorable safety profile, with only mild inflammation noted. This promising data will support their FDA Investigational New Drug Application (IND) submission. Virpax focuses on developing non-addictive pain management therapies.